Skip to main content
Download PDF

Association between SUMF1 polymorphisms and COVID-19 severity

BMC Genomic Data volume 24, Article number: 34 (2023) Cite this article

Abstract

Background

Evidence shows that genetic factors play important roles in the severity of coronavirus disease 2019 (COVID-19). Sulfatase modifying factor 1 (SUMF1) gene is involved in alveolar damage and systemic inflammatory response. Therefore, we speculate that it may play a key role in COVID-19.

Results

We found that rs794185 was significantly associated with COVID-19 severity in Chinese population, under the additive model after adjusting for gender and age (for C allele = 0.62, 95% CI = 0.44–0.88, P = 0.0073, logistic regression). And this association was consistent with this in European population Genetics Of Mortality In Critical Care (GenOMICC: OR for C allele = 0.94, 95% CI = 0.90–0.98, P = 0.0037). Additionally, we also revealed a remarkable association between rs794185 and the prothrombin activity (PTA) in subjects (P = 0.015, Generalized Linear Model).

Conclusions

In conclusion, our study for the first time identified that rs794185 in SUMF1 gene was associated with the severity of COVID-19.

Peer Review reports

Introduction

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide, and has lasted for more than two years. So far, more than 570 million cases have been reported [1]. To date, many new SARS-CoV-2 variants have been observed, and these new variants have different epidemiological and biological characteristics [2,3,4]. The clinical spectrum of SARS-CoV-2 infection starts from mild influenza-like symptoms to severe pneumonia, and even acute respiratory distress syndrome (ARDS) and multiple organ failure [5,6,7,8,9]. The asymptomatic infection subjects and mild patients have a good prognosis after isolation [10, 11]. However, moderate, severe and critical patients still need special treatment, and the prognosis of severe and critical patients is poor, even leading to death [5, 12, 13]. Therefore, the study on the severity of COVID-19 is very important. One important line of research is the use of machine learning to understand and fight COVID-19. And this is currently an active research field. In many studies, machine learning has been proved to be very helpful in predicting the severity and mortality of COVID-19 [14,15,16,17]. It is beneficial to rational planning of medical resources. But only socio-demographic and presenting clinical data was used as input in most of the research on machine learning. Previous studies have shown that host genetic variation is related to the severity of COVID-19 [18,19,20,21]. And genetic determinism plays an important role in predicting the severity of COVID-19 and etiological guidance, which can provide a theoretical basis for individualized treatment of patients. The purpose of this study is to provide genetic ideas for predicting the severity of COVID-19.

Compared to other respiratory viruses, SARS-CoV-2 elicits a stronger, perduring, auto-aggressive inflammatory response [22], fueled by a massive cytokine release, causing coagulation dysfunction and multiple organ dysfunction syndrome in severe cases [23]. The occurrence and severity of COVID-19 largely depends on the host’s response to the infection, which echoes several aspects of Multiple sclerosis (MS) pathobiology. MS is a common neurological disease, which was caused by the failure of the immune system, characterized by persistent inflammation, demyelination and irreparable damage to the central nervous system [24, 25]. Like other autoimmune diseases, MS is associated with genetic factors [26]. Genome-wide association studies (GWASs) have observed a significant association between a single nucleotide polymorphism (SNP) rs794185 in sulfatase modifying factor 1 (SUMF1) gene and MS (P < 6.44 × 10− 7) [27]. SUMF1 is biologically plausible for susceptibility to MS. For example, mutations in SUMF1 could lead to multiple sulphatase deficiency and may indirectly regulate extracellular glutamate by altering the activity of steroid sulphatases, leading to neuroaxonal cell death, which is contributing aetiological factor in MS [28, 29]. Like immune disorder of MS, severe COVID-19 is also related to the “cytokine” storm caused by immune imbalance [30,31,32]. We speculated that COVID-19 and MS might have the same susceptibility gene. However, there are no studies showing a relationship between SUMF1 gene and COVID-19. Here, we aimed to assess the possible association between SUMF1 gene polymorphism (rs794185) and the severity of COVID-19.

Results

Characteristics of participants

The participants consisted of 285 cases and 141 controls, among which, 242 subjects were female, and 184 subjects were male. A significant difference was found in gender between the two groups (P = 0.010, Chi-square test). In addition, we also analyzed the difference of age, and it was significant between two groups (45.6 ± 18.0 vs. 29.8 ± 16.9, P < 0.001, Mann–Whitney U test). Compared to the individuals in control group, subjects from case group were older (Table 1). The laboratory indexes of case and control groups showed that white blood cell (WBC), neutrophil (NE), lymphocyte (LY), basophil (BAS), red blood cell (RBC), hemoglobin (HB), albumin (ALB), total bilirubin (TBIL), direct bilirubin (DBIL), fibrinogen (FIB), thrombin time (TT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and serum amyloid A (SAA) were significantly different between two groups (P < 0.05, Mann–Whitney U test) (Table 2).

Table 1 Clinical characteristics of the COVID-19 patients
Full size table
Table 2 Laboratory indexes of the study participants
Full size table

Association analysis between rs794185 and COVID-19 severity in the Chinese Han population and European population

Basic information of rs794185 in SUMF1 gene was described in Table 4. In this study, rs794185 was genotyped using the Sequenom MassARRAY System. The calling rate of rs794185 was 99.77%. The Hardy-Weinberg equilibrium (HWE) tests in both case and control groups showed that SNP rs794185 could be subjected to further analysis (P > 0.05; Table 3).

Table 3 Hardy-Weinberg equilibrium tests for rs794185
Full size table

The genotype frequencies of rs794185 in control and case groups are shown in Table 4. Association analysis revealed that the risk of severe COVID-19 at the rs794185 site of the SUMF1 gene was significantly reduced using TT genotype as a reference in the Chinese Han population under the additive model after adjusting for gender and age (odds ratio [OR] for C allele = 0.62, 95% CI = 0.44–0.88, P = 0.0073, logistic regression).

Table 4 Association between rs794185 and COVID-19 severity in the Chinese Han population
Full size table

After checking rs794185 in SUMF1 gene in European population from an online public database Genetics Of Mortality In Critical Care (GenOMICC), we found that the result was consistent with this identified in the Chinese Han population. The risk of severe COVID-19 at the rs794185 site of the SUMF1 gene was also significantly reduced in European population (GenOMICC: OR for C allele = 0.94, 95% CI = 0.90–0.98, P = 0.0037; Table 5).

Table 5 rs794185 in European population from online public resource
Full size table

Stratification analyses: association between rs794185 and COVID-19 severity by gender or age

To eliminate potential confounding effects caused by age and gender, we further evaluated the alleles and COVID-19 severity stratified by age and gender (Table 6). The lower risk of severe COVID-19 was more evident among younger subjects (≤ 65 years old, OR = 0.72, 95% CI = 0.52-1.00, P = 0.0486, logistic regression) carrying the C allele. No apparent associations between rs794185 and COVID-19 severity were found in male and female (P > 0.05; Table 6).

Table 6 Stratification analyses: association between rs794185 and COVID-19 severity by gender or age
Full size table

Association analyses between observed genotypes and clinical values

Association analyses between the observed genotypes and the clinical values were performed by GLM procedure (Table 7). The result revealed that there was a significant association between rs794185 and Prothrombin time activity (PTA) (P = 0.015, GLM).

Table 7 Association analyses between observed genotypes and clinical values
Full size table

Discussion

At present, the global epidemic continues. Studies have shown that age, sex, blood type, virulence of pathogens, and underlying diseases are related to the severity of COVID-19 [33,34,35,36]. But genetic factors of the individual also play an important role in the pathogenesis of COVID-19. So far, studies have reported that several polymorphisms are related to the susceptibility or severity of COVID-19, but these polymorphisms are different among different populations [37]. Obviously, the genetic determinant of COVID-19 severity is still unknown. The strong association with autoimmunity was peculiar of SARS-CoV-2 with respect to other Coronaviruses and respiratory viruses. Interestingly, MS-associated genes were mostly enriched in SARS-CoV-2 host’s interactors, suggesting pathophysiological overlaps that are worth investigating [38]. In particular, there are three pivotal crossroads of MS and COVID-19 immunological substrates: the type-1 IFN (IFN-I) response, the TH-17 axis, and the inflammasome pathway [39]. And a study by Moss et al. looked at the impact of the coronavirus pandemic on multiple sclerosis care at three centers, including the Cleveland Clinic, Johns Hopkins Hospital, and CEMCAT in Barcelona. The survey-based study surveyed 3028 patients with MS and found 77 (2.5%) suspected or confirmed cases of COVID-19. They found that these patients were more likely to know or live with COVID-19 patients [40]. These studies suggest us some genetic factors of COVID-19 largely overlap with MS. SUMF1 gene polymorphism rs794185, as a genetic factor significantly related to autoimmune disease MS, has been confirmed by GWAS [27]. The possible reason is the deficiency of sulfatase caused by rs794185 variation. Therefore, we speculate that rs794185 is related to the severity of COVID-19.

So far, there are no studies showing the relationship between SUMF1 gene and COVID-19 severity. But in our study, we found a significant association between rs794185 in SUMF1 gene and COVID-19 severity (P = 0.0073). Subjects carrying the rs794185 locus C allele of the SUMF1 gene had a lower risk of severe COVID-19. In Han Chinese subjects younger than 65 years of age, C allele carriers had a 0.72-fold reduced risk of severe COVID-19 compared to subjects with the T allele. And this significant association has been confirmed in European population in a COVID-19 GWAS online database. Also, according to the Genotype-Tissue Expression (GTEx) database (http://www.gtexportal.org/home/), expression quantitative trait loci (eQTL) analyses have indicated that rs794185 variant was associated with SUMF1 gene expression in whole blood (P = 3.9 × 10− 7) [27]. Otherwise, several studies observed that SUMF1 (-/-) mice developed emphysema-like phenotype following an arrest of alveolarization, and even systemic inflammation and neurodegeneration [41, 42]. Then, other studies showed that SUMF1 gene variation increased the risk of Chronic Obstructive Pulmonary Disease (COPD) by affecting the expression, activity and localization in lung fibroblasts [43,44,45]. This suggests that the association between SUMF1 and COVID-19 severity may be due to the following two factors.

On the one hand, SUMF1 mutation causes pulmonary function decline by affecting alveolar function. Alveolar formation or alveolization is coordinated by fine regulation and complex interactions between growth factors and extracellular matrix proteins [46]. In the lung, glycosaminoglycans (GAGs) are dispersed in the extracellular matrix (ECM) [47]. Sulfatase activity requires a unique posttranslational modification, which is performed by SUMF1 [48, 49], making it active to desulfate GAGs. It has been confirmed that sulfatase cannot be fully activated in SUMF1 (-/-) mice. Highly sulfated GAG is deposited in the alveoli, which reduces the alveolar septum and increases the alveolar volume, resulting in decreased lung function [42]. Moreover, the role of GAGs in respiratory disease has been heightened by the current COVID-19 pandemic. GAGs are known to regulate growth factor distribution and activity according to their degree of sulfation. When SUMF1 is mutated, highly sulfated GAGs promote growth factor β (TGF-β) signaling and the upregulation of TGF-β signaling in the lung has been observed in the SUMF1 (-/-) mice. There is a developmental arrest in alveolar formation that reduces lung function. Bronchopulmonary dysplastic-like lungs due to suppression of alveolar septation were observed in transgenic mice with over expression of TGF-β between postnatal days 7 and 14 [50]. Similar results were obtained in neonatal rats overexpressing TGF-β [51]. And it has been confirmed by experiments in vivo injection of TGF-β neutralizing antibody leads to normalization of alveolarization [42]. These lung injuries have similarities with early-phase ARDS, a clinical manifestation in patients with severe COVID-19 [12, 52]. And some studies have shown that the level of serum TGF-β in severe COVID-19 group is significantly higher than that in the control group, which can predict the severe disease [53,54,55]. Also, application of TGF-β inhibitors will also relieve COVID-19 symptoms and sequelae [56,57,58]. At the same time, it also provides a new target for the treatment of lung tissue remodeling after COVID-19.

On the other hand, SUMF1 gene mutations can cause a series of systemic responses. The mutations of SUMF1 gene cause a decrease of sulfatase activity because of a post-translational modification defect [59]. And mammals have a single sulfate enzyme modification system. A team of researchers observed that in SUMF1 (-/-) mice sulfatase activities were completely absent. All examined tissues showed progressive cell vacuolization and significant lysosomal storage of GAGs. And they detected a strong increase in the expression levels of inflammatory cytokines and of apoptotic markers in both the central nervous system and liver [41]. In the pathophysiology of ARDS induced by SARS-CoV-2, the overproduction of early response proinflammatory cytokines results in what has been described as a cytokine storm, leading to an increased risk of vascular hyperpermeability, multiorgan failure, and eventually death when the high cytokine concentrations are unabated over time [5]. It was demonstrated that the mutation of SUMF1 gene caused systemic multisystem diseases including systemic inflammation, apoptosis and neurodegeneration. And this combined clinical symptom caused by sulfatase deficiency has also been observed in human individuals [60,61,62]. And the severity of the disease is related to the stability and residual activity of formylglycine generating enzyme (FGE) by the SUMF1 gene encoding [63]. So, systemic multi-system dysfunction caused by SUMF1 gene mutations may also promote the occurrence of severe COVID-19.

Additionally, activation of coagulation pathways during the immune response to SARS-CoV-2 infection results in overproduction of proinflammatory cytokines leading to multiorgan injury [5]. Our analyses revealed a remarkable association between rs794185 genotype and the PTA in patients (P = 0.015). This may be related to the coagulation dysfunction caused by COVID-19 [64, 65]. PTA is an important index reflecting liver coagulation function. Thrombin generation is tightly controlled by negative feedback loops and physiological anticoagulants, such as antithrombin III, tissue factor pathway inhibitor, and the protein C system [66]. During inflammation, all three of these control mechanisms can be impaired, with reduced anticoagulant concentrations due to reduced production and increasing consumption. This defective procoagulant–anticoagulant balance predisposes to the development of microthrombosis, disseminated intravascular coagulation, and multiorgan failure-evidenced in severe COVID-19 pneumonia with raised d-dimer concentrations being a poor prognostic feature and disseminated intravascular coagulation common in non-survivors [67, 68] So far, many studies have reported that COVID-19-induced coagulopathy (CIC) is commonly encountered [64, 69, 70]. While all coagulation parameters can be affected by COVID-19, there is considerable variability in the extent of these alterations and their correlation to disease severity and mortality [68, 71]. In addition to the impaired coagulation function caused by impaired liver function, it is speculated that the dysregulated immune responses orchestrated by inflammatory cytokines, lymphocyte cell death, hypoxia, and endothelial damage are involved [65]. Anyway, this finding contributes to early recognition of coagulation abnormalities among hospitalized COVID-19 patients.

Otherwise, our study has several limitations. Firstly, as a single-center study, the number of samples available is limited. In particular, the sample size of severe and critical patients in this study is small, while the proportion of severe and critical patients in European population is higher. So the verification about GenOMICC data is not very accurate. However, to some extent, it can reflect the relationship between SUMF1 gene and the severity of COVID-19. In addition, it would be better to add other evaluation indicators for comprehensive analysis, such as lung function, lung CT.

Conclusion

In summary, our study for the first time identified that rs794185 in SUMF1 gene was associated with the severity of COVID-19. The risk of severe COVID-19 at the rs794185 site of the SUMF1 gene was significantly reduced using TT genotype as a reference. This may be related to alveolar injury, systemic immune response and nervous system damage caused by infection.

This discovery might provide novel insights into the pathogenesis and clinical treatment of COVID-19. For clinicians, it can be used as a reference for predicting the severity of COVID-19. And it can help clinicians to plan medical resources effectively.

Of course, this result also needs larger sample size, multicenter research to systematically verify. In particular, it is necessary to expand the sample size of severe and critical patients.

Methods

Subject recruitment

In this study, we recruited 426 patients with SARS-CoV-2 infection in the Fifth Hospital of Shijiazhuang during January 2020 to May 2021, including 141 asymptomatic infection subjects, 261 moderate, 23 severe patients and 1 critical patient. The diagnosis of COVID-19 was made by a confirmed SARS-CoV-2 infection from nasopharyngeal swabs using real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay. With reference to the Diagnosis and Treatment Protocol for COVID-19 (version 9.0), asymptomatic infection subjects were only positive for RT-PCR without any discomfort symptoms. According to ‘Diagnosis and Treatment Protocol for COVID-19’, the manifestation of “Moderate” stage included fever, respiratory symptoms and radiological evidence of pneumonia. The severe COVID-19 patients were those patients who had more severe clinical symptoms: respiratory distress, respiratory rate ≥ 30 beats/minute; means oxygen saturation ≤ 93% in a resting state; and arterial blood oxygen partial pressure/oxygen concentration ≤ 300 mmHg. In Critical stage, patients had at least one of the following symptoms: shock incidence; respiratory failure and requiring mechanical ventilation; and admission to intensive care unit (ICU) with other organ function failure. The classification of patients was based on the most serious classification during hospitalization. These assessments were done and checked by at least two experienced respiratory physicians. To identify the susceptibility loci contributing to severity of COVID-19, these subjects were divided into control group (asymptomatic infection subjects) and case group (hospitalized COVID-19 patients, i.e., moderate, severe and critical COVID-19 patients) according to the clinical characteristics. After obtaining the consent of the study participants, all information related to age, sex, laboratory indicators and disease types were recorded. The study was approved by the Medical Ethics Management Committee of the Fifth Hospital of Shijiazhuang (Ethics batch number: 202,230,714,010,258). Written informed consent was obtained from each participant. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations.

DNA extraction and genotyping

The whole blood samples of these patients (285 cases and 141 controls) were collected and cryopreserved with EDTA-containing tube at -80℃ until measurement. DNA was isolated according to the manufacturer’s instructions of Nucleic Acid Isolation or Purification Kit of DAAN GENE Company. The quantity and quality of the isolated genomic DNA were verified using two methods: (1) the DNA degradation and contamination were monitored on 1% agarose gels; and (2) the DNA concentration was measured using a Qubit 4.0 Fluorometer.

To genotype the SNP rs794185, we used the Sequenom MassARRAY System according to the manufacturer’s instructions (Sequenom) [72]. Briefly, locus-specific PCR and detection primers were designed using the MassARRAY Assay Design 3.0 software (Table 8). Approximate 15 ng of genomic DNAs for each sample were amplified by multiplex PCR, and the PCR products were then used for locus-specific single-base extension reactions. The resulting products were desalted and transferred to a 384-element SpectroCHIP array. Allele detection was performed using MALDI-TOF MS. The mass spectrograms were analyzed by the MassARRAY TYPER software (Sequenom). The cluster patterns of the genotyping data from Sequenom analyses were visually checked to confirm their good quality. For further quality control, 5% of the individuals in this study were randomly selected for repeated genotyping, and the results were 100% concordant.

Table 8 Primer sequences of rs794185
Full size table

Association analysis between SUMF1 polymorphism and COVID-19 severity

The distribution frequencies of genotypes of rs794185 in the case group and the control group were analyzed in the Chinese Han population. After the Hardy-Weinberg equilibrium (HWE) test, the association analysis was carried out with PLINK software package (v1.9) [73]. We carried out SNP association analysis using logistic regression under an additive model with adjustment for age and gender.

To verify our result in European population, we checked an online public resource: Genetics Of Mortality In Critical Care (GenOMICC) (release 2) (an online public resource accessed from https://genomicc.org/data/) in 7,491 critically-ill cases with COVID-19 and 48,400 population controls. The associations were considered to be statistically significant when P < 0.05.

Statistical analyses

Genotypes, clinical characteristics and laboratory indexes collected in Excel software were entered and then analyzed. The Chi-square test (χ2), Fisher’s exact test and Mann–Whitney U test were performed to compare the differences of clinical characteristics and laboratory indexes between the cases and controls using SPSS statistical software version 21.0. Generalized Linear Model (GLM) procedure was applied to test the association between observed genotypes and clinical values. Continuous and categorical variables were expressed as mean ± standard deviation and as percentages, respectively. Logistic regression was performed by using PLINK software package (v1.9). Significant level in all tests is considered 0.05.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its Supplementary information files], the GenOMICC (release 2: 7491 critical Covid cases) (https://genomicc.org/data/) and the GTEx (release V8) websites (http://www.gtexportal.org/home/).

Abbreviations

COVID-19:

Coronavirus disease 2019

SUMF1 :

Sulfatase modifying factor 1

OR:

Odds ratio

PTA:

Prothrombin activity

GenOMICC:

Genetics Of Mortality In Critical Care

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2

ARDS:

Acute respiratory distress syndrome

MS:

Multiple sclerosis

GWAS:

Genome-wide association study

SNP:

Single nucleotide polymorphism

CI:

Confidence interval

SD:

Standard deviation

ALB:

Albumin

ALT:

Alanine transaminase

APTT:

Activated partial thromboplastin time

AST:

Aspartate Aminotransferase

BAS:

Basophil

BUN:

Blood urea nitrogen

CRP:

C-reactive protein

DBIL:

Directbilirubin

EOS:

Eosinophil

ESR:

Erythrocyte sedimentation rate

FIB:

Fibrinogen

HB:

Hemoglobin

IBIL:

Indirect bilirubin

INR:

International normalized ratio

LY:

Lymphocyte

MONO:

Monocyte

NE:

Neutrophil

PLT:

Platelet

PT:

Prothrombin time

RBC:

Red blood cell

SAA:

Serum amyloid A

Scr:

Serum creatinine

TBIL:

Total bilirubin

TT:

Thrombintime

WBC:

White blood cell.

MAF:

Minor allele frequency

HWE:

Hardy–Weinberg equilibrium

GLM:

Generalized Linear Model

GTEx:

Genotype-Tissue Expression

eQTL:

Expression quantitative trait loci

COPD:

ChronicObstructive Pulmonary Disease

GAGs:

Glycosaminoglycans

ECM:

Extracellular matrix

TGF-β:

Transforming growth factorβ

FGE:

Formylglycine generating enzyme

CIC:

COVID-19-induced coagulopathy

RT-PCR:

Real-timereverse transcriptase polymerase chain reactio

ICU:

Intensive care unit

References

  1. Homepage on the internet. [http://www.coronavirus.jhu.edu. Accessed 29 July 2022].

  2. Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol. 2022;94(7):2986–3005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cui Z, Liu P, Wang N, Wang L, Fan K, Zhu Q, Wang K, Chen R, Feng R, Jia Z, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 2022;185(5):860–871e813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7.

    Article  CAS  PubMed  Google Scholar 

  6. Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022;94(6):2376–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22(12):757–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021;28(7):taab124.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, Ma K. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12–6.

    Article  CAS  PubMed  Google Scholar 

  11. Barboza JJ, Chambergo-Michilot D, Velasquez-Sotomayor M, Silva-Rengifo C, Diaz-Arocutipa C, Caballero-Alvarado J, Garcia-Solorzano FO, Alarcon-Ruiz CA, Albitres-Flores L, Malaga G, et al. Assessment and management of asymptomatic COVID-19 infection: a systematic review. Travel Med Infect Dis. 2021;41:102058.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93.

    Article  CAS  PubMed  Google Scholar 

  13. Kurihara C, Manerikar A, Querrey M, Felicelli C, Yeldandi A, Garza-Castillon R Jr, Lung K, Kim S, Ho B, Tomic R, et al. Clinical characteristics and outcomes of patients with COVID-19-Associated Acute Respiratory Distress Syndrome who underwent Lung Transplant. JAMA. 2022;327(7):652–61.

    Article  CAS  PubMed  Google Scholar 

  14. Alballa N, Al-Turaiki I. Machine learning approaches in COVID-19 diagnosis, mortality, and severity risk prediction: a review. Inf Med Unlocked. 2021;24:100564.

    Article  Google Scholar 

  15. Patel D, Kher V, Desai B, Lei X, Cen S, Nanda N, Gholamrezanezhad A, Duddalwar V, Varghese B, Oberai AA. Machine learning based predictors for COVID-19 disease severity. Sci Rep. 2021;11(1):4673.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cobre AF, Stremel DP, Noleto GR, Fachi MM, Surek M, Wiens A, Tonin FS, Pontarolo R. Diagnosis and prediction of COVID-19 severity: can biochemical tests and machine learning be used as prognostic indicators? Comput Biol Med. 2021;134:104531.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chadaga K, Prabhu S, Umakanth S, Sampathila KV, K KPJES. COVID-19 mortality prediction among patients using epidemiological parameters. An Ensemble Machine Learning Approach; 2021.

  18. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324(7):663–73.

    Article  PubMed  Google Scholar 

  19. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Beck DB, Aksentijevich I. Susceptibility to severe COVID-19. Science. 2020;370(6515):404–5.

    Article  PubMed  Google Scholar 

  21. Li Y, Ke Y, Xia X, Wang Y, Cheng F, Liu X, Jin X, Li B, Xie C, Liu S, et al. Genome-wide association study of COVID-19 severity among the chinese population. Cell Discov. 2021;7(1):76.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity. 2020;52(6):905–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, et al. Complex Immune Dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992–1000e1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27(3):271–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021;17(11):676–88.

    Article  PubMed  Google Scholar 

  26. Baranzini SE, Oksenberg JR. The Genetics of multiple sclerosis: from 0 to 200 in 50 years. Trends Genet. 2017;33(12):960–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR, Pelletier D. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain. 2010;133(9):2603–11.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ahrens-Nicklas R, Schlotawa L, Ballabio A, Brunetti-Pierri N, De Castro M, Dierks T, Eichler F, Ficicioglu C, Finglas A, Gaertner J, et al. Complex care of individuals with multiple sulfatase deficiency: clinical cases and consensus statement. Mol Genet Metab. 2018;123(3):337–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Adang LA, Schlotawa L, Groeschel S, Kehrer C, Harzer K, Staretz-Chacham O, Silva TO, Schwartz IVD, Gartner J, De Castro M, et al. Natural history of multiple sulfatase deficiency: retrospective phenotyping and functional variant analysis to characterize an ultra-rare disease. J Inherit Metab Dis. 2020;43(6):1298–309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ramasamy S, Subbian S. Critical determinants of Cytokine Storm and Type I Interferon Response in COVID-19 pathogenesis. Clin Microbiol Rev. 2021;34(3):e00299–00220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370(6520):eabd4250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chen PZ, Bobrovitz N, Premji ZA, Koopmans M, Fisman DN, Gu FX. SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19. Elife. 2021;10:e70458.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11(1):5761.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wanhella KJ, Fernandez-Patron C. Biomarkers of ageing and frailty may predict COVID-19 severity. Ageing Res Rev. 2022;73:101513.

    Article  CAS  PubMed  Google Scholar 

  37. Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, Symons A, Esparza-Gordillo J, and Me C-T, Aslibekyan S, et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet. 2021;53(6):801–8.

  38. Bellucci G, Ballerini C, Mechelli R, Bigi R, Rinaldi V, Renie R, Buscarinu MC, Baranzini SE, Madireddy L, Matarese G, et al. SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. F1000Res. 2020;9:992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bellucci G, Rinaldi V, Buscarinu MC, Renie R, Bigi R, Pellicciari G, Morena E, Romano C, Marrone A, Mechelli R, et al. Multiple sclerosis and SARS-CoV-2: has the interplay started? Front Immunol. 2021;12:755333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hollen C, Bernard J. Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep. 2022;22(8):537–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Settembre C, Annunziata I, Spampanato C, Zarcone D, Cobellis G, Nusco E, Zito E, Tacchetti C, Cosma MP, Ballabio A. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. Proc Natl Acad Sci U S A. 2007;104(11):4506–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Arteaga-Solis E, Settembre C, Ballabio A, Karsenty G. Sulfatases are determinants of alveolar formation. Matrix Biol. 2012;31(4):253–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Weidner J, Jarenback L, de Jong K, Vonk JM, van den Berge M, Brandsma CA, Boezen HM, Sin D, Bosse Y, Nickle D, et al. Sulfatase modifying factor 1 (SUMF1) is associated with chronic obstructive Pulmonary Disease. Respir Res. 2017;18(1):77.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Weidner J, Jogdand P, Jarenback L, Aberg I, Helihel D, Ankerst J, Westergren-Thorsson G, Bjermer L, Erjefalt JS, Tufvesson E. Expression, activity and localization of lysosomal sulfatases in Chronic Obstructive Pulmonary Disease. Sci Rep. 2019;9(1):1991.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Jarenback L, Frantz S, Weidner J, Ankerst J, Nihlen U, Bjermer L, Wollmer P, Tufvesson E. Single-nucleotide polymorphisms in the sulfatase-modifying factor 1 gene are associated with lung function and COPD. ERJ Open Res. 2022;8(2):0668–2021.

    Article  Google Scholar 

  46. Roth-Kleiner M, Post M. Similarities and dissimilarities of branching and septation during lung development. Pediatr Pulmonol. 2005;40(2):113–34.

    Article  PubMed  Google Scholar 

  47. Caird R, Williamson M, Yusuf A, Gogoi D, Casey M, McElvaney NG, Reeves EP. Targeting of Glycosaminoglycans in genetic and inflammatory Airway Disease. Int J Mol Sci. 2022;23(12):6400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Diez-Roux G, Ballabio A. Sulfatases and human disease. Annu Rev Genomics Hum Genet. 2005;6:355–79.

    Article  CAS  PubMed  Google Scholar 

  49. Fraldi A, Biffi A, Lombardi A, Visigalli I, Pepe S, Settembre C, Nusco E, Auricchio A, Naldini L, Ballabio A, et al. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem J. 2007;403(2):305–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vicencio AG, Lee CG, Cho SJ, Eickelberg O, Chuu Y, Haddad GG, Elias JA. Conditional overexpression of bioactive transforming growth factor-beta1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? Am J Respir Cell Mol Biol. 2004;31(6):650–6.

    Article  CAS  PubMed  Google Scholar 

  51. Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med. 1997;214(1):27–40.

    Article  CAS  PubMed  Google Scholar 

  52. Gosangi B, Rubinowitz AN, Irugu D, Gange C, Bader A, Cortopassi I. COVID-19 ARDS: a review of imaging features and overview of mechanical ventilation and its complications. Emerg Radiol. 2022;29(1):23–34.

    Article  PubMed  Google Scholar 

  53. Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323.

    Article  CAS  PubMed  Google Scholar 

  54. Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, et al. Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600(7888):295–301.

    Article  CAS  PubMed  Google Scholar 

  55. Barros-Martins J, Forster R, Bosnjak B. NK cell dysfunction in severe COVID-19: TGF-beta-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity. Signal Transduct Target Ther. 2022;7(1):32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent Post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021:1–9.

  57. Vaz de Paula CB, Nagashima S, Liberalesso V, Collete M, da Silva FPG, Oricil AGG, Barbosa GS, da Silva GVC, Wiedmer DB, da Silva Deziderio F, et al. COVID-19: immunohistochemical analysis of TGF-beta signaling pathways in Pulmonary Fibrosis. Int J Mol Sci. 2021;23(1):168.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Chen W. A potential treatment of COVID-19 with TGF-beta blockade. Int J Biol Sci. 2020;16(11):1954–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Schlotawa L, Adang LA, Radhakrishnan K, Ahrens-Nicklas RC. Multiple sulfatase Deficiency: a Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and more caused by a defect in Posttranslational Modification. Int J Mol Sci. 2020;21(10):3448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Schlotawa L, Ennemann EC, Radhakrishnan K, Schmidt B, Chakrapani A, Christen HJ, Moser H, Steinmann B, Dierks T, Gartner J. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011;19(3):253–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Sabourdy F, Mourey L, Le Trionnaire E, Bednarek N, Caillaud C, Chaix Y, Delrue MA, Dusser A, Froissart R, Garnotel R, et al. Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet J Rare Dis. 2015;10:31.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Busche A, Hennermann JB, Burger F, Proquitte H, Dierks T, von Arnim-Baas A, Horn D. Neonatal manifestation of multiple sulfatase deficiency. Eur J Pediatr. 2009;168(8):969–73.

    Article  CAS  PubMed  Google Scholar 

  63. Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J. Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. Hum Mutat. 2008;29(1):205.

    Article  PubMed  Google Scholar 

  64. Hadid T, Kafri Z, Al-Katib A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2021;47:100761.

    Article  CAS  PubMed  Google Scholar 

  65. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Jose RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 2014;69(2):190–2.

    Article  PubMed  Google Scholar 

  67. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lin J, Yan H, Chen H, He C, Lin C, He H, Zhang S, Shi S, Lin K. COVID-19 and coagulation dysfunction in adults: a systematic review and meta-analysis. J Med Virol. 2021;93(2):934–44.

    Article  CAS  PubMed  Google Scholar 

  71. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Li Y, Zhai Y, Song Q, Zhang H, Cao P, Ping J, Liu X, Guo B, Liu G, Song J, et al. Genome-wide Association Study identifies a new locus at 7q21.13 Associated with Hepatitis B Virus-Related Hepatocellular Carcinoma. Clin Cancer Res. 2018;24(4):906–15.

    Article  PubMed  Google Scholar 

  73. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all the patients participating in this study, and express our condolences to the families of patients who died from COVID-19.

Funding

This work was supported by grants from Immune profiling of COVID-19 patients based on Mass Cytometry (202230714010258). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Author notes

  1. Shaohui Liang, Huixia Gao and Tongxin He contributed equally to this work.

Authors and Affiliations

  1. Department of Respiratory, Hebei Chest Hospital, Shijiazhuang, 050000, Hebei, China

    Shaohui Liang, Jie Bao & Yong Gao

  2. Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, Hebei, China

    Huixia Gao & Erhei Dai

  3. College of Plant Protection, Hunan Agricultural University, Changsha, 410128, Hunan, China

    Tongxin He

  4. Intensive Care Unit, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, Hebei, China

    Li Li

  5. Department of Tuberculosis, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, Hebei, China

    Xin Zhang & Yuling Wang

  6. The Second Internal Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, 050021, Hebei, China

    Lei Zhao

  7. Graduate School of Hebei Medical University, Shijiazhuang, 050017, Hebei, China

    Jie Chen, Yanyan Xie & Yuling Wang

Authors
  1. Shaohui Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huixia Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tongxin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jie Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yanyan Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jie Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yong Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Erhei Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuling Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SL, HG, ED and YW substantially contributed to the study design. SL and HG recruited subjects, extracted DNA, researched data, and wrote the manuscript. TH, LL and XZ conducted statistical analysis and interpreted the results; LZ, JC and YX took responsibility for the integrity of the data and accuracy of the data analysis; JB, YG, TH and SL reanalyzed the data and revised the manuscript; YW and ED are the guarantor. All authors reviewed the manuscript and approved this version to be published.

Corresponding authors

Correspondence to Erhei Dai or Yuling Wang.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Medical Ethics Management Committee of the Fifth Hospital of Shijiazhuang (202230714010258). Written informed consent was obtained from all participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Genotypes of rs794185 in the Chinese Han population. Table S2. Snp rs794185 location information.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liang, S., Gao, H., He, T. et al. Association between SUMF1 polymorphisms and COVID-19 severity. BMC Genom Data 24, 34 (2023). https://0-doi-org.brum.beds.ac.uk/10.1186/s12863-023-01133-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12863-023-01133-6

Keywords

BMC Genomic Data

ISSN: 2730-6844

Contact us